$16.70+0.04 (+0.24%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Xeris Biopharma Holdings (XERS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
1 figure withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~55.8%/yr (FY21→FY25), net margin 0.2%, and free cash flow (~$27.9M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+118.6%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($K)▲43.7%
291,845.0
FY21→FY25CAGR +55.8%/yr
Net income ($K)—
554.0
FY21→FY25CAGR —
Free cash flow ($K)—
27,930.0
FY21→FY25CAGR —
Diluted EPS—
0.00
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+118.6%
79.0mn → 172.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$696.0K
−19.8% YoY in FY25 · 0.2% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)
0¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 73.1% → 85.4%. Net margin 0.2% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 368,259.0 | 291,845.0 | 203,070.0 | 163,914.0 | 110,248.0 | 49,590.0 | ▲43.7% | +55.8% |
Cost of revenue | 46,462.0 | 42,569.0 | 36,832.0 | 28,645.0 | 22,634.0 | 13,318.0 | ▲15.6% | +33.7% |
Gross profit | 321,797.0 | 249,276.0 | 166,238.0 | 135,269.0 | 87,614.0 | 36,272.0 | ▲50.0% | +61.9% |
Research & development | 38,384.0 | 31,165.0 | 25,560.0 | 22,341.0 | 20,966.0 | 25,160.0 | ▲21.9% | +5.5% |
Selling, general & admin | 225,789.0 | 182,372.0 | 163,481.0 | 146,095.0 | 137,745.0 | 125,718.0 | ▲11.6% | +9.7% |
Total operating expenses | 275,016.0 | 224,380.0 | 199,884.0 | 179,279.0 | 169,554.0 | 151,428.0 | ▲12.3% | +10.3% |
Operating incomefeeds ROC rank | 46,781.0 | 24,896.0 | −33,646.0 | −44,010.0 | −81,940.0 | −115,156.0 | — | — |
Other income, net | −53,277.0 | −24,342.0 | −23,458.0 | −19,494.0 | −14,144.0 | −7,569.0 | — | — |
Pretax income | −6,496.0 | 554.0 | −57,104.0 | −63,504.0 | −96,084.0 | −122,725.0 | — | — |
Income tax | — | 0.0 | −2,268.0 | −1,249.0 | −1,424.0 | 0.0 | — | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | −6,496.0 | 554.0 | −54,836.0 | −62,255.0 | −94,660.0 | −122,725.0 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.04 | 0.00 | −0.37 | −0.45 | −0.70 | −1.55 | — | — |
Diluted shares (mn) | 189.92 | 172.74 | 146.77 | 137.67 | 135.63 | 79.03 | ▲17.7% | +21.6% |
| Margins | ||||||||
Gross margin82nd pct in Healthcare | 87.4% | 85.4% | 81.9% | 82.5% | 79.5% | 73.1% | ▲3.6pp | +12.3pp |
Operating margin | 12.7% | 8.5% | −16.6% | −26.8% | −74.3% | −232.2% | ▲25.1pp | +240.7pp |
Net margin36th pct in Healthcare | −1.8% | 0.2% | −27.0% | −38.0% | −85.9% | −247.5% | ▲27.2pp | +247.7pp |
† TTM = trailing four quarters through 2026-09-30.
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-02 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Xeris Biopharma Holdings' revenue last fiscal year?
Xeris Biopharma Holdings reported revenue of $291,845.0K in fiscal 2025, up 43.7% from fiscal 2024.
What was Xeris Biopharma Holdings' net income?
Xeris Biopharma Holdings reported net income of $554.0K in fiscal 2025, a net margin of 0.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

